Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Joleen M. Hubbard; Axel Grothey

doi:10.1038/nrclinonc.2014.233

Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Joleen M. Hubbard, Axel Grothey

Medical Oncology

Research output: Contribution to journal › Review article

25 Scopus citations

Abstract

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

Original language	English (US)
Pages (from-to)	19-20
Number of pages	2
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/nrclinonc.2014.233
State	Published - Jan 1 2015

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1038/nrclinonc.2014.233

Fingerprint Dive into the research topics of 'Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies'. Together they form a unique fingerprint.

Cite this

Hubbard, J. M., & Grothey, A. (2015). Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies. Nature Reviews Gastroenterology and Hepatology, 12(1), 19-20. https://doi.org/10.1038/nrclinonc.2014.233

@article{b4ef6fad683f43b7a0680524757c80dd,

title = "Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies",

abstract = "The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.",

author = "Hubbard, {Joleen M.} and Axel Grothey",

year = "2015",

month = jan,

day = "1",

doi = "10.1038/nrclinonc.2014.233",

language = "English (US)",

volume = "12",

pages = "19--20",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Colorectal cancer in 2014

T2 - Progress in defining first-line and maintenance therapies

AU - Hubbard, Joleen M.

AU - Grothey, Axel

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

AB - The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84923202077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923202077&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2014.233

DO - 10.1038/nrclinonc.2014.233

M3 - Review article

C2 - 25560533

AN - SCOPUS:84923202077

VL - 12

SP - 19

EP - 20

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 1

ER -